Guide editing system based on circular RNA

By developing a guided editing system based on circular RNA, the Cas12 series proteins are coupled with reverse transcriptase, the problem of Cas9 protein limitation is solved, and efficient and precise editing of the genome of the organism is achieved, which is suitable for a variety of organisms.

CN118995701APending Publication Date: 2024-11-22INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410608629.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing guide editing system relies on the Cas9 protein, and has many limitations such as target sequence selection and organism delivery. The newly discovered nucleases such as the Cas12 series proteins have not been effectively applied to more functional guide editors.

Method used

Develop a guided editing system based on circular RNA, using non-targeted strand single nick enzymes such as Cas12a, Cas12b, etc. to couple with reverse transcriptase, to achieve accurate base insertion, deletion and replacement of the genome of the organism, and through multiple Simultaneous expression and tandem of RNA improve editing efficiency.

Benefits of technology

Overcoming the limitations of Cas9 protein, it achieves efficient and precise editing of the genome of the organism, and is suitable for various organisms such as human cells and plants, improving the flexibility and efficiency of gene editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004844411740000011
    Figure HDA0004844411740000011
  • Figure HDA0004844411740000021
    Figure HDA0004844411740000021
  • Figure HDA0004844411740000031
    Figure HDA0004844411740000031
Patent Text Reader

Abstract

The invention relates to the field of gene engineering. Specifically, the invention relates to a circular RNA (Ribonucleic Acid)-based guided editing system for realizing fixed-point and accurate genome editing. More specifically, according to the guide editing system based on the circular RNA, nuclease except Cas9 or single nicking enzyme is coupled with reverse transcriptase, and accurate base insertion, deletion and replacement are carried out on a target sequence in an organism genome based on the circular RNA; as well as genetically modified but non-transgenic organisms and progeny thereof produced by the method.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of genetic engineering. Specifically, the present invention relates to a circular RNA-based guide editing system for achieving site-specific, precise genome editing. More specifically, the circular RNA-based guide editing system of the present invention utilizes nucleases other than Cas9 or single-nickases coupled to reverse transcriptase, and based on circular RNA, achieves precise base insertion, deletion and replacement of target sequences in the genome of an organism, as well as genetically modified but non-transgenic organisms and their offspring produced by the method. Background of the Invention

[0003] With the rapid development of biology, precise editing of the genome of organisms has become an urgent need for medical treatment, agriculture and scientific research. Precise genome editing technology can treat a large number of genetic diseases in medicine, create excellent agricultural traits in agriculture, and promote the development of biology. There are three main types of commonly used precise base editing systems: cytosine base editor (CBE), adenine base editor (ABE) and prime editor (PE). Among them, the cytosine base editor can realize the conversion of cytosine (C) to uracil (U) at the target site; the adenine base editor can realize the conversion of adenine (A) to hypoxanthine (I); the prime editor can realize the conversion and transversion of various single bases, and can realize the insertion, deletion and replacement of fragments. It can be seen that the function of prime editing is more powerful, but the prime editor currently used only has the reverse enzyme coupled to the Cas9 protein, which is limited by the Cas9 protein in many aspects such as the selection of target sequences and delivery to organisms. The Cas12 series of proteins discovered later: Cas12a (ie Cpf1), Cas12b (ie C2c1), Cas12c, Cas12d (ie CasY), Cas12e (ie CasX), Cas12f (ie Cas14), Cas12h, Cas12i, Cas12j (ie CasΦ), Cas12k, Cas12m and smaller IsrB, IscB and TnpB proteins have structural characteristics different from Cas9, and each has unique functional advantages. For example, Cpf1 has the advantages of high efficiency and low off-target rate; Cas12f, IsrB, IscB and TnpB proteins have the advantages of small sequence and easy delivery. Most of these protein-fused base deaminases have good applications in cytosine base editors and adenine base editors. But to date, these large numbers of newly discovered proteins have not been applied to guide editors with richer functions. Therefore, the development of a new guide editing system that is independent of Cas9 protein using proteins such as Cas12a (i.e., Cpf1), Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IsrB, IscB and TnpB will overcome the limitations of Cas9 protein, effectively utilize the advantages of other proteins, better promote the application of guide editors, and play a very important role in disease treatment, agricultural trait improvement and biological research. Brief description of the invention

[0005] The present invention has developed a novel circular RNA-dependent Prime Editing system (CPE, Circular RNA-dependent Prime Editing system, Figure 1 According to the type of protein used in the prime editing, CPE is further divided into a prime editing system that uses a non-targeted strand single nickase and relies on circular RNA (niCPE, Circular RNA-dependent Prime Editing system with nickase, Figure 1 a) and nuCPE (Circular RNA-dependent Prime Editing system with nuclease, Figure 1 b). At the same time, in order to facilitate delivery, we developed a split sniCPE (split Circular RNA-dependent PrimeEditing system with nickase, Figure 1 c) and snuCPE (split Circular RNA-dependent PrimeEditing system with nuclease) guide editing systems. In addition, we also found that multiple RNAs can be expressed in tandem, and on this basis, we developed an efficient one-CPE (All RNA under one U6 promoter CPE) guide editing system. More importantly, we can achieve multi-gene editing in HEK293T human cell lines using the Cas12a-CPE system. The CPE-guided editing system will further achieve precise genome editing of single-base conversions and transversions, fragment insertions, deletions, and replacements in animals, bacteria, dicots, monocots, and other organisms. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 : Schematic diagram of different boot editing systems.

[0008] Figure 2 : Editing efficiency of the copGFP reporter system for different guide editing systems.

[0009] Figure 3 : Comparison of guide editing efficiency using pegRNA and circular RNA.

[0010] Figure 4 :The editing efficiency of the Cas12a-niCPE-guided editing system in different editing modes at various target sites in human 293T cells.

[0011] Figure 5 : Editing efficiency of the Cas12a-nuCPE-guided editing system in human 293T cells.

[0012] Figure 6 : Editing efficiency of the Cas12a-sniCPE-guided editing system in human 293T cells.

[0013] Figure 7 : Editing efficiency of the Cas12a-snuCPE-guided editing system in human 293T cells.

[0014] Figure 8 : Comparison of editing efficiency of different guided editing systems.

[0015] Fig. 9 : one-CPE boot editing system.

[0016] Fig.10 : A multi-gene guided editing system.

[0017] Fig.11 : Off-Target Detection of CPE Using a Circular RNA-Guided Editing System.

[0018] Fig.12 : Editing efficiency of Cas12i-nuCPE and Cas12i-niCPE-guided editing systems in human 293T cells. DETAILED DESCRIPTION OF THE INVENTION

[0020] I. Definition

[0021] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology related terms and laboratory operation procedures used herein are terms and routine procedures widely used in the corresponding fields. For example, the standard recombinant DNA and molecular cloning techniques used in the present invention are well known to those skilled in the art and are more fully described in the following documents: Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter referred to as "Sambrook"). At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0022] As used herein, the term "and / or" encompasses all combinations of items connected by the term, and each combination should be considered to have been listed separately herein. For example, "A and / or B" encompasses "A," "A and B," and "B." For example, "A, B, and / or C" encompasses "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."

[0023] When the term "comprising" is used herein to describe a protein or nucleic acid sequence, the protein or nucleic acid may consist of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still have the activity described in the present invention. In addition, it is clear to those skilled in the art that the methionine encoded by the start codon at the N-terminus of the polypeptide may be retained in certain practical situations (for example, when expressed in a specific expression system), but it does not substantially affect the function of the polypeptide. Therefore, when describing a specific polypeptide amino acid sequence in the specification and claims of this application, although it may not contain a methionine encoded by a start codon at the N-terminus, a sequence containing the methionine is also covered at this time, and accordingly, its encoding nucleotide sequence may also contain a start codon; and vice versa.

[0024] "Genome" as used herein encompasses not only the chromosomal DNA present in the cell nucleus, but also the organellar DNA present in subcellular components of the cell (eg, mitochondria, plastids).

[0025] As used herein, "organism" includes any organism suitable for genome editing, preferably a eukaryotic organism. Examples of organisms include, but are not limited to, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, Arabidopsis, etc.

[0026] "Genetically modified organism" means an organism plant that contains exogenous polynucleotides or modified genes or expression control sequences in its genome. For example, exogenous polynucleotides can be stably integrated into the genome of the organism and inherited for consecutive generations. Exogenous polynucleotides can be integrated into the genome alone or as part of a recombinant DNA construct. The modified gene or expression control sequence is one in which the gene or expression control sequence contains one or more nucleotide substitutions, deletions, and additions in the plant genome.

[0027] "Exogenous" with respect to a sequence refers to a sequence that is from a foreign species, or, if from the same species, a sequence that has been significantly altered in composition and / or locus from its native form through deliberate human intervention.

[0028] "Polynucleotide", "nucleic acid sequence", "nucleotide sequence" or "nucleic acid fragment" are used interchangeably and are single-stranded or double-stranded RNA or DNA polymers, optionally containing synthetic, non-natural or altered nucleotide bases. Nucleotides are referred to by their single letter names as follows: "A" is adenosine or deoxyadenosine (RNA or DNA, respectively), "C" represents cytidine or deoxycytidine, "G" represents guanosine or deoxyguanosine, "U" represents uridine, "T" represents deoxythymidine, "R" represents purine (A or G), "Y" represents pyrimidine (C or T), "K" represents G or T, "H" represents A or C or T, "D" represents A, T or G, "I" represents inosine, and "N" represents any nucleotide. Although nucleotide sequences herein may be represented as DNA sequences (including T), when RNA is referred to, the corresponding RNA sequence can be easily determined by a skilled artisan (i.e., replacing T with U).

[0029] "Polypeptide", "peptide", and "protein" are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers. The terms "polypeptide", "peptide", "amino acid sequence" and "protein" may also include modified forms, including but not limited to glycosylation, lipid attachment, sulfation, gamma carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.

[0030] As used herein, "expression construct" refers to a vector such as a recombinant vector suitable for expressing a nucleotide sequence of interest in an organism. "Expression" refers to the production of a functional product. For example, the expression of a nucleotide sequence can refer to the transcription of the nucleotide sequence (such as transcription to generate mRNA or functional RNA) and / or the translation of RNA into a precursor or mature protein.

[0031] The "expression construct" of the present invention can be a linear nucleic acid fragment, a circular plasmid, a viral vector, or, in some embodiments, can be a translatable RNA (such as mRNA), for example, RNA generated by in vitro transcription. For use in mammals such as humans, the expression construct is preferably a viral vector, such as an adeno-associated virus (AAV), a lentivirus, an adenoviral vector, and most preferably an AAV vector.

[0032] An "expression construct" of the present invention may comprise regulatory sequences and a nucleotide sequence of interest from different sources, or regulatory sequences and a nucleotide sequence of interest from the same source but arranged in a manner different from that normally found in nature.

[0033] "Promoter" refers to a nucleic acid fragment that can control the transcription of another nucleic acid fragment. In some embodiments of the present invention, a promoter is a promoter that can control the transcription of a gene in a cell, whether or not it is derived from the cell. A promoter can be a constitutive promoter or a tissue-specific promoter or a developmentally regulated promoter or an inducible promoter.

[0034] Examples of promoters include, but are not limited to, polymerase (pol) I, pol II or pol III promoters. Examples of pol I promoters include chicken RNA pol I promoters. Examples of pol II promoters include, but are not limited to, cytomegalovirus immediate early (CMV) promoters, Rous sarcoma virus long terminal repeat (RSV-LTR) promoters, and simian virus 40 (SV40) immediate early promoters. Examples of pol III promoters include U6, U3, and H1 promoters. Inducible promoters such as metallothionein promoters can be used. Other examples of promoters include T7 phage promoters, T3 phage promoters, β-galactosidase promoters, and Sp6 phage promoters. When used for plants, the promoter can be a cauliflower mosaic virus 35S promoter, a corn Ubi-1 promoter, a wheat U6 promoter, a rice U3 promoter, a corn U3 promoter, and a rice actin promoter.

[0035] "Introducing" a nucleic acid molecule (e.g., a plasmid, a linear nucleic acid fragment, RNA, etc.) or a protein into an organism refers to transforming an organism cell with the nucleic acid or protein so that the nucleic acid or protein can function in the cell. "Transformation" as used in the present invention includes stable transformation and transient transformation. "Stable transformation" refers to the introduction of an exogenous nucleotide sequence into a genome, resulting in stable inheritance of the exogenous gene. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any successive generations thereof. "Transient transformation" refers to the introduction of a nucleic acid molecule or protein into a cell, performing a function without stable inheritance of the exogenous gene. In transient transformation, the exogenous nucleic acid sequence is not integrated into the genome.

[0036] "Trait" refers to a physiological, morphological, biochemical, or physical characteristic of a cell or organism.

[0037] 2. Guide the editing system

[0038] In one aspect, the present invention provides a guide editing system for targeted modification of a genomic DNA sequence of an organism, comprising:

[0039] i) a) a CRISPR nuclease and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease, and a reverse transcriptase and / or an expression construct comprising a nucleotide sequence encoding said reverse transcriptase, or

[0040] b) a guide editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the guide editing fusion protein, wherein the guide editing fusion protein comprises a CRISPR nuclease and a reverse transcriptase;

[0041] ii) an editing guide RNA (gRNA) directed against a target sequence in genomic DNA and / or an expression construct containing a nucleotide sequence encoding the editing gRNA; and

[0042] iii) a circular RNA containing a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence and / or an expression construct containing a nucleotide sequence encoding the circular RNA,

[0043] Preferably, the CRISPR nuclease is not a Cas9 nuclease or a variant thereof.

[0044] As used herein, "guide editing system" refers to a combination of components required for reverse transcription-based genome editing of the genome in a cell. The various components of the system, such as CRISPR nuclease, reverse transcriptase, guide editing fusion protein, gRNA, circular RNA or their expression constructs, etc., can exist independently of each other, or can exist in the form of a composition in any combination. The various components of the system can be packaged into viruses, virus-like particles, virions, liposomes, vesicles, exosomes, liposome nanoparticles (LNPs), etc. independently or together.

[0045] The CRISPR nuclease of the present invention may be a CRISPR nuclease other than a Cas9 nuclease or a variant thereof. Examples of CRISPR nucleases suitable for the present invention include, but are not limited to, Cas12a (i.e., Cpf1), Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IsrB, IscB, and TnpB. In some specific embodiments, the CRISPR nuclease is Cas12a. In other specific embodiments, the CRISPR nuclease is Cas12i.

[0046] In some embodiments, the CRISPR nuclease also includes a nickase form thereof. The nickase form of the CRISPR nuclease may also be referred to herein as a CRISPR nickase, which forms a nick in only one strand of a double-stranded nucleic acid molecule, but does not completely cut off the double-stranded nucleic acid. In some embodiments, the CRISPR nickase forms a nick only in the complementary strand of the strand where the target sequence is located in the double-stranded nucleic acid molecule (also referred to as a non-targeted strand in this area).

[0047] As used herein, "target sequence" refers to a sequence of about 20 nucleotides in length characterized by a PAM (protospacer sequence adjacent motif) sequence flanking the 5' or 3' flank in the genome. Generally speaking, PAM is necessary for the complex formed by CRISPR nuclease or its variants and guide RNA to recognize the target sequence. For example, for Cas12a nuclease and its variants, its target sequence is adjacent to PAM at the 3' end, such as 5'-TTTV-3'. Based on the presence of PAM, those skilled in the art can easily determine the target sequence that can be used for targeting in the genome. And depending on the position of PAM, the target sequence can be located on any strand of the genomic DNA molecule, the strand bound by crRNA is called the targeting strand, and the strand complementary to the targeting strand is called the non-targeting strand. For Cas12a or its derivatives such as Cas12a nickase, the target sequence is preferably 20 to 23 nucleotides. Depending on different CRISPR nucleases or their different variants, the PAM sequence will be different.

[0048] In some specific embodiments, the CRISPR nuclease is Cas12a, which comprises the amino acid sequence shown in SEQ ID NO: 1 or 2. In some preferred embodiments, the CRISPR nuclease is a Cas12a nickase, which is substituted at the amino acid position 1138 relative to SEQ ID NO: 1 or 2, for example, the amino acid R at position 1138 is substituted by A. In some preferred embodiments, the CRISPR nuclease comprises the amino acid sequence shown in SEQ ID NO: 3.

[0049] In some specific embodiments, the CRISPR nuclease is Cas12i, which comprises the amino acid sequence shown in SEQ ID NO: 4. In some preferred embodiments, the CRISPR nuclease is a Cas12i nickase, which is substituted at the amino acid position 854 relative to SEQ ID NO: 4, for example, the amino acid W at position 854 is substituted by A. In some preferred embodiments, the Cas12i nickase comprises the amino acid sequence shown in SEQ ID NO: 5.

[0050] The reverse transcriptase in the present invention can be derived from different sources. In some embodiments, the reverse transcriptase is a reverse transcriptase derived from a virus. For example, in some embodiments, the reverse transcriptase is M-MLV reverse transcriptase. An exemplary wild-type M-MLV reverse transcriptase sequence is shown in SEQ ID NO:6 as an amino acid sequence.

[0051] In some embodiments, the RNase H domain of the reverse transcriptase, such as M-MLV reverse transcriptase, is mutated or deleted. In some embodiments, the M-MLV reverse transcriptase with a mutated or deleted RNase H domain comprises the amino acid sequence shown in SEQ ID NO:7.

[0052] In some embodiments, the reverse transcriptase and / or the guide editing fusion protein of the present invention may further comprise one or more RNA aptamer binding protein sequences. In some embodiments, the reverse transcriptase of the present invention further comprises one or more RNA aptamer binding protein sequences. In some embodiments, the guide editing fusion protein of the present invention further comprises one or more RNA aptamer binding protein sequences.

[0053] "RNA aptamer binding protein" refers to a protein that can specifically bind to an "RNA aptamer" having a specific sequence and structure. Proteins containing one or more RNA aptamer binding protein sequences can thus be recruited to nucleic acid molecules containing corresponding RNA aptamers in cells, and vice versa. Many such combinations of "RNA aptamer binding proteins" and "RNA aptamers" that can specifically bind are known in the art.

[0054] In some embodiments, the RNA aptamer binding protein is MCP protein, and the corresponding RNA aptamer is MS2. MCP protein can specifically bind to MS2 or multiple MS2s in series. An exemplary MCP comprises the amino acid sequence shown in SEQ ID NO: 8. An exemplary MS2 comprises the nucleotide sequence shown in SEQ ID NO: 17.

[0055] As used herein, a "linker" can be a non-functional amino acid sequence of 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 20-25, 25-50) or more amino acids in length and without secondary or higher structure. For example, the linker can be a flexible linker. In some specific embodiments, the linker comprises the amino acid sequence shown in SEQ ID NO: 9.

[0056] In some embodiments of the present invention, the CRISPR nuclease, reverse transcriptase, or guide editing fusion protein of the present invention may also include one or more nuclear localization sequences (NLS). In general, one or more NLSs in the CRISPR nuclease, reverse transcriptase, or guide editing fusion protein should have sufficient strength to drive the CRISPR nuclease, reverse transcriptase, or guide editing fusion protein to accumulate in the nucleus of the cell in an amount that can achieve its gene editing function. In general, the intensity of nuclear localization activity is determined by the number, position, one or more specific NLSs used, or a combination of these factors in the CRISPR nuclease, reverse transcriptase, or guide editing fusion protein. An exemplary NLS may include the amino acid sequence shown in SEQ ID NO: 10 or 11.

[0057] However, depending on the DNA location to be edited, the CRISPR nuclease, reverse transcriptase, or guide editing fusion protein of the present invention may also include other localization sequences, such as cytoplasmic localization sequences, chloroplast localization sequences, mitochondrial localization sequences, etc.

[0058] In some embodiments, the guide editing fusion protein comprises an amino acid sequence selected from one of SEQ ID NOs: 12-15, preferably comprises the amino acid sequence of SEQ ID NO:12.

[0059] In some embodiments, the guided editing system comprises:

[0060] i) a guide editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the guide editing fusion protein, wherein the guide editing fusion protein comprises an amino acid sequence selected from one of SEQ ID NOs: 12-15, preferably comprises the amino acid sequence of SEQ ID NO: 12;

[0061] ii) an editing guide RNA (gRNA) and / or an expression construct containing a nucleotide sequence encoding the editing gRNA; and

[0062] iii) a circular RNA comprising a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence and / or an expression construct comprising a nucleotide sequence encoding the circular RNA.

[0063] In some embodiments, the guided editing system comprises:

[0064] i) a CRISPR nuclease and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease, and a reverse transcriptase and / or an expression construct comprising a nucleotide sequence encoding said reverse transcriptase;

[0065] ii) an editing guide RNA (gRNA) and / or an expression construct containing a nucleotide sequence encoding the editing gRNA; and

[0066] iii) a circular RNA containing a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence and / or an expression construct containing a nucleotide sequence encoding the circular RNA,

[0067] wherein the CRISPR nuclease comprises an amino acid sequence selected from one of SEQ ID NOs: 1-5, preferably an amino acid sequence of SEQ ID NOs: 3 or 5,

[0068] The reverse transcriptase comprises the amino acid sequence shown in SEQ ID NO:16.

[0069] In order to obtain effective expression in different organisms, in the present invention, the nucleotide sequence encoding the CRISPR nuclease, reverse transcriptase, or guide editing fusion protein can be codon-optimized for the organism species whose genome is to be modified.

[0070] Codon optimization refers to a method of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon of the native sequence (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) with codons that are more frequently or most frequently used in the genes of the host cell while maintaining the native amino acid sequence. Different species exhibit specific preferences for certain codons for specific amino acids. Codon bias (differences in codon usage between organisms) is often correlated with the efficiency of translation of messenger RNA (mRNA), which in turn is believed to depend on the nature of the codons being translated and the availability of specific transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell generally reflects the codons that are most frequently used for peptide synthesis. Therefore, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, in the Codon Usage Database available at www.kazusa.orjp / codon / , and these tables can be adapted for use in different ways. See, Nakamura et al., 2001. Y. et al., "Codon usage tabulated from the international DNA sequence databases: status for the year 2000. Nucl. Acids Res., 28:292 (2000).

[0071] The guide RNA (gRNA) of the present invention refers to a gRNA compatible with the CRISPR nuclease. gRNA may generally include a scaffold sequence and a guide sequence (also known as a seed sequence or spacer sequence). The guide sequence is set to have sufficient sequence identity (preferably 100% identity) with the target sequence, so that it can bind to the complementary strand of the target sequence through base pairing to achieve sequence-specific targeting. The scaffold sequence generally depends on the CRISPR nuclease used. For example, for Cas12a such as LbCas12a, the scaffold sequence of its gRNA may include the nucleotide sequence shown in SEQ ID NO:23. And for Cas12i, the scaffold sequence of its gRNA may include the nucleotide sequence shown in SEQ ID NO:24. CRISPR nuclease can bind to the scaffold sequence of gRNA and form a CRISPR nuclease-gRNA complex, and target to the genomic target sequence under the action of the guide sequence, and exert its nuclease or nickase function. Those skilled in the art can design suitable gRNA for different CRISPR nucleases and different target sequences. The guide RNA targeting the target sequence to be edited is referred to as editing guide RNA (editing gRNA) in the present invention.

[0072] The "circular RNA" of the present invention contains a directly connected reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence (RTT-PBS sequence), wherein the RTT sequence is located at the 5' end of the PBS sequence.

[0073] In some embodiments, the circular RNA further comprises one or more (e.g., 1 or 2 or 3 or more) RNA aptamer sequences, such as MS2 sequences. The one or more RNA aptamer sequences in the circular RNA can be used to recruit a reverse transcriptase containing an RNA aptamer binding protein in a cell, or to recruit the circular RNA to a CRISPR nuclease-gRNA-genomic DNA complex in a cell.

[0074] In some embodiments, the primer binding site sequence is set to be complementary to at least a portion of the target sequence (preferably completely matched with at least a portion of the target sequence), preferably, the primer binding site sequence is complementary to at least a portion of the 3' free single strand caused by the nick in the DNA chain where the target sequence is located (preferably completely matched with at least a portion of the 3' free single strand), in particular, complementary to the nucleotide sequence at the 3' end of the 3' free single strand (preferably completely matched). When the 3' free single strand of the chain binds to the primer binding sequence through base pairing, the 3' free single strand can serve as a primer, using the reverse transcription template sequence adjacent to the primer binding site sequence as a template, and reverse transcription is performed under the action of the reverse transcriptase in the guide editing fusion protein or the reverse transcriptase recruited by the RNA aptamer binding protein, extending a DNA sequence corresponding to the reverse transcription template (RTT) sequence.

[0075] The primer binding site sequence depends on the length of the free single strand formed by the CRISPR nuclease used in the strand where the target sequence is located, however, it should have a minimum length to ensure specific binding. In some embodiments, the primer binding site sequence length can be 4-20 nucleotides, for example, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides in length.

[0076] The RTT sequence can be any sequence. Through the above-mentioned reverse transcription, its sequence information can be integrated into the DNA chain where the target sequence is located (that is, the chain containing the target sequence PAM), and then through the DNA repair action of the cell, a DNA double-stranded chain containing the RTT sequence information is formed. In some embodiments, the RTT sequence contains desired modifications. For example, the desired modification includes substitution, deletion and / or addition of one or more nucleotides. In some embodiments, the RTT sequence is set to correspond to a sequence downstream of the target sequence incision (for example, complementary to at least a portion of the sequence downstream of the target sequence incision), but contains desired modifications. The desired modification includes substitution, deletion and / or addition of one or more nucleotides.

[0077] In some embodiments, the guide editing system further comprises a nicking gRNA (nicking gRNA, for producing additional nicks) and / or an expression construct containing a nucleotide sequence encoding the nicking gRNA, wherein the nicking gRNA comprises a guide sequence and a scaffold sequence. In some preferred embodiments, the nicking gRNA does not comprise a reverse transcription (RT) template sequence and a primer binding site (PBS) sequence.

[0078] The guide sequence (also called seed sequence or spacer sequence) in the nicking gRNA of the present invention is set to have sufficient sequence identity (preferably 100% identity) with the nicking target sequence in the genome, so that the fusion protein of the present invention can be targeted to the nicking target sequence and cause a nick in the nicking target sequence, and the nicking target sequence and the target sequence targeted by the editing gRNA (target sequence to be edited) are located on the opposite strand of the genomic DNA. In some embodiments, the nick formed by the nicking RNA and the nick formed by the editing gRNA are about 1-about 300 or more nucleotides apart, for example, 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300 nucleotides or more nucleotides apart. In some embodiments, the nick formed by the nicking RNA is located upstream or downstream of the editing gRNA (the upstream or downstream refers to the DNA chain where the editing gRNA target sequence is located). In some embodiments, the leader sequence in the nicking gRNA has sufficient sequence identity (preferably 100% identity) with the relative chain (modified) of the editing gRNA target sequence after the editing event occurs, so that the nicking gRNA only targets the nicking target sequence generated after the editing gRNA-induced target sequence targeting and modification are completed. In some embodiments, the PAM of the nicking target sequence is located within the complementary sequence of the editing gRNA target sequence.

[0079] In some embodiments, the guide editing system comprises multiple (e.g., 2, 3, 4, 5 or more) editing gRNAs and / or an expression construct containing a nucleotide sequence encoding the multiple editing gRNAs.

[0080] Accordingly, in some embodiments, the circular RNA comprises multiple groups (e.g., 2, 3, 4, 5 or more) of RTT-PBS sequences corresponding to the multiple editing gRNAs in series, each group of RTT-PBS sequences comprises a directly connected reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence, and the RTT sequence is located at the 5' end of the PBS sequence. In some embodiments, the multiple editing gRNAs target different target sequences, and the corresponding multiple groups of RTT-PBS sequences are used to introduce different modifications, so that the guide editing system can target and modify different target sequences.

[0081] The "expression construct containing a nucleotide sequence encoding the circular RNA" of the present invention may also contain elements required for achieving RNA cyclization. The elements may refer to Jacob L. Litke et al., Nature Biotechnology, Vol 37, June 2019, 667–675, or Wesselhoeft AR et al., (2018) Engineering circular RNA for potent and stable translation in eukaryotic cells. Other elements known in the art that can achieve RNA cyclization may also be used in the present invention.

[0082] In some embodiments, the "expression construct containing a nucleotide sequence encoding the circular RNA" includes the following coding sequence: 5'-first ribozyme-first looping arm-RTT-PBS-second looping arm-second ribozyme-3'. After being transcribed into RNA in the cell, the first ribozyme and the second ribozyme can self-cleave to produce "5'-first looping arm-RTT-PBS-second looping arm-3'", and the first looping arm and the second looping arm can be connected to each other to form a circular RNA containing RTT and PBS. In some embodiments, the two sides of the RTT-PBS can also contain one or more RNA aptamer sequences such as MS2 sequences.

[0083] In some embodiments, the first ribozyme comprises the nucleotide sequence of SEQ ID NO: 19. In some embodiments, the second ribozyme comprises the nucleotide sequence of SEQ ID NO: 20. In some embodiments, the first looping arm comprises the nucleotide sequence of SEQ ID NO: 21. In some embodiments, the second looping arm comprises the nucleotide sequence of SEQ ID NO: 22.

[0084] In some embodiments, the editor gRNA and the circular RNA and the optional nick gRNA are encoded by the same expression construct. In some embodiments, the expression construct comprises (e.g., from 5' to 3' direction) a nucleotide sequence encoding the circular RNA, a nucleotide sequence encoding the editor gRNA, and an optional nucleotide sequence encoding the nick gRNA. In some embodiments, the nucleotide sequence encoding the circular RNA, the nucleotide sequence encoding the editor gRNA, and the optional nucleotide sequence encoding the nick gRNA are driven to express (transcribe) by the same promoter such as the U6 promoter. Due to the RNA cleavage activity of the CRISPR nuclease / nickase for crRNA maturation, the RNA molecules transcribed by the same promoter can produce respective circular RNAs, editor gRNAs, and optional nick gRNAs.

[0085] On the other hand, the present invention provides a Cas12a nickase and / or an expression construct comprising a coding sequence thereof, wherein the amino acid at position 1138 is substituted relative to SEQ ID NO: 1 or 2, for example, the amino acid R at position 1138 is substituted by A. In some preferred embodiments, the Cas12a nickase comprises the amino acid sequence shown in SEQ ID NO: 3.

[0086] On the other hand, the present invention provides a Cas12i nickase and / or an expression construct comprising a coding sequence thereof, wherein relative to SEQ ID NO: 4, the amino acid at position 854 is substituted, for example, the amino acid W at position 854 is substituted by A. In some preferred embodiments, the Cas12i nickase comprises the amino acid sequence shown in SEQ ID NO: 5.

[0087] On the other hand, the present invention provides the use of the Cas12a nickase or Cas12i nickase of the present invention, or an expression construct comprising its coding sequence in gene editing, such as guide editing.

[0088] 3. Methods for modifying target sequences in cell genomes

[0089] In another aspect, the present invention provides a method for producing a genetically modified cell, comprising introducing the guide editing system of the present invention into at least one of the cells, thereby resulting in modification of the genome sequence of the at least one cell. The modification comprises substitution, deletion and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, such as 1 to about 100 or more, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions. The modification can be located in the target sequence of the gRNA or near the target sequence, for example, downstream of the target sequence.

[0090] In another aspect, the present invention also provides a method for producing a genetically modified cell, comprising introducing the guide editing system of the present invention into the cell.

[0091] In another aspect, the present invention also provides a genetically modified organism comprising a genetically modified cell produced by the method of the present invention or a progeny cell thereof.

[0092] In the present invention, the modification can be located at any position of the genome, for example, in a functional gene such as a protein coding gene, or, for example, in a gene expression regulatory region such as a promoter region or an enhancer region, thereby achieving modification of the gene function or modification of gene expression. The modification in the cell genome sequence can be detected by T7EI, PCR / RE or sequencing methods.

[0093] In the method of the present invention, the guide editing system can be introduced into cells by various methods well known to those skilled in the art.

[0094] Methods that can be used to introduce the guide editing system of the present invention into cells include, but are not limited to, calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as baculovirus, vaccinia virus, adenovirus, adeno-associated virus, lentivirus and other viruses), gene gun technique, PEG-mediated protoplast transformation, and Agrobacterium-mediated transformation.

[0095] Cells that can be gene-edited by the methods of the present invention can be derived from, for example, prokaryotes such as bacteria; eukaryotes including: mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants, including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, Arabidopsis, etc. In some preferred embodiments, the cells are from humans.

[0096] In some embodiments, the methods of the invention are performed in vitro. For example, the cells are isolated cells, or cells in isolated tissues or organs.

[0097] In other embodiments, the method of the present invention can also be performed in vivo. For example, the cell is a cell in an organism, and the system of the present invention can be introduced into the cell in vivo by, for example, a virus or Agrobacterium-mediated method.

[0098] IV. Methods for producing genetically modified plants

[0099] In another aspect, the present invention provides a method for producing a genetically modified plant, comprising introducing the guide editing system of the present invention into at least one of the plants, thereby causing a modification in the genome of the at least one plant. The modification comprises substitution, deletion and / or addition of one or more nucleotides. For example, the modification comprises one or more substitutions selected from the group consisting of C to T substitutions, C to G substitutions, C to A substitutions, G to T substitutions, G to C substitutions, G to A substitutions, A to T substitutions, A to G substitutions, A to C substitutions, T to C substitutions, T to G substitutions, T to A substitutions; and / or comprises a deletion of one or more nucleotides, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide deletions; and / or comprises an insertion of one or more nucleotides, such as 1 to about 100 or more, such as 1 to about 100 or more, such as 1, 2, 3, 4, 5, about 10, about 20, about 30, about 40, about 50, about 75, about 100 nucleotide insertions.

[0100] In some embodiments, the method further comprises screening the at least one plant for plants having the desired modification.

[0101] In the method of the present invention, the guide editing system can be introduced into plants by various methods well known to those skilled in the art. Methods that can be used to introduce the guide editing system of the present invention into plants include, but are not limited to, gene gun method, PEG-mediated protoplast transformation, Agrobacterium-mediated transformation, plant virus-mediated transformation, pollen tube channel method, and ovary injection method. Preferably, the guide editing system is introduced into plants by transient transformation.

[0102] In the method of the present invention, the genome modification can be achieved by simply introducing or producing relevant proteins and RNA in plant cells, and the modification can be stably inherited without the need to stably transform the exogenous polynucleotides encoding the components of the guide editing system into plants. This avoids the potential off-target effects of the stably existing (continuously produced) editing system and also avoids the integration of exogenous nucleotide sequences in the plant genome, thereby having higher biosafety.

[0103] In some preferred embodiments, the introduction is performed in the absence of selection pressure, thereby avoiding integration of the exogenous nucleotide sequence into the plant genome.

[0104] In some embodiments, the introduction comprises transforming the guide editing system of the present invention into isolated plant cells or tissues, and then regenerating the transformed plant cells or tissues into complete plants. Preferably, the regeneration is performed in the absence of selection pressure, that is, no selection agent for the selection gene carried on the expression vector is used during tissue culture. Not using a selection agent can improve the regeneration efficiency of the plant and obtain a modified plant that does not contain exogenous nucleotide sequences.

[0105] In other embodiments, the guide editing system of the present invention can be transformed into specific parts of the whole plant, such as leaves, stem tips, pollen tubes, young panicles or hypocotyls. This is particularly suitable for the transformation of plants that are difficult to regenerate through tissue culture.

[0106] In some embodiments of the invention, the in vitro expressed protein and / or in vitro transcribed RNA molecule (e.g., the expression construct is an in vitro transcribed RNA molecule) is directly transformed into the plant. The protein and / or RNA molecule can achieve guided editing in plant cells and then be degraded by the cells, avoiding the integration of exogenous nucleotide sequences in the plant genome.

[0107] Therefore, in some embodiments, genetic modification and breeding of plants using the methods of the present invention can obtain plants whose genomes have no exogenous polynucleotides integrated, ie, non-transgenic (transgene-free) modified plants.

[0108] In some embodiments of the present invention, the modified genomic region is associated with a plant trait such as an agronomic trait, whereby the modification substitution results in the plant having an altered (preferably improved) trait, such as an agronomic trait, relative to a wild-type plant.

[0109] In some embodiments, the method further comprises the step of screening plants for desired modifications and / or desired traits, such as agronomic traits.

[0110] In some embodiments of the present invention, the method further comprises obtaining offspring of the genetically modified plant. Preferably, the genetically modified plant or its offspring has a desired modification and / or a desired trait such as an agronomic trait.

[0111] On the other hand, the present invention also provides a genetically modified plant or its offspring or its part, wherein the plant is obtained by the above-mentioned method of the present invention. In some embodiments, the genetically modified plant or its offspring or its part is non-transgenic. Preferably, the genetically modified plant or its offspring has a desired genetic modification and / or a desired trait such as an agronomic trait.

[0112] In another aspect, the present invention also provides a plant breeding method, comprising hybridizing a first genetically modified plant obtained by the above method of the present invention with a second plant not containing the modification, thereby introducing the modification into the second plant. Preferably, the first genetically modified plant has a desired trait such as an agronomic trait.

[0113] "Agronomic traits" specifically refer to measurable indicator parameters of crop plants, including but not limited to: leaf green, grain yield, growth rate, total biomass or accumulation rate, fresh weight at maturity, dry weight at maturity, fruit yield, seed yield, plant total nitrogen content, fruit nitrogen content, seed nitrogen content, plant vegetative tissue nitrogen content, plant total free amino acid content, fruit free amino acid content, seed free amino acid content, plant vegetative tissue free amino acid content, plant total protein content, fruit protein content, seed protein content, plant vegetative tissue protein content, herbicide resistance and drought resistance, nitrogen absorption, root lodging, harvest index, stem lodging, plant height, ear height, ear length, disease resistance, cold resistance, salt resistance and tillering number, etc.

[0114] 5. Therapeutic Application

[0115] The present invention also covers the use of the guided editing system of the present invention in disease treatment.

[0116] By modifying the disease-related genes through the guide editing system of the present invention, it is possible to achieve upregulation, downregulation, inactivation, activation or mutation correction of the disease-related genes, thereby achieving disease prevention and / or treatment. For example, the genome modification described in the present invention can be located in the protein coding region of the disease-related gene, or, for example, can be located in a gene expression regulatory region such as a promoter region or an enhancer region, so as to achieve functional modification of the disease-related gene or modification of the expression of the disease-related gene. Therefore, the modified disease-related genes described herein include modification of the disease-related gene itself (e.g., protein coding region), and also include modification of its expression regulatory region (e.g., promoter, enhancer, intron, etc.).

[0117] "Disease-related" gene refers to any gene that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from tissues affected by the disease, compared to tissues or cells of non-disease controls. In the case where the altered expression is related to the appearance and / or progression of the disease, it can be a gene expressed at an abnormally high level; it can be a gene expressed at an abnormally low level. Disease-related genes also refer to genes with one or more mutations or genetic variations that are directly responsible or unbalanced with one or more genes responsible for the etiology of the disease. The mutation or genetic variation is, for example, a single nucleotide variation (SNV). The transcribed or translated product can be known or unknown, and can be at normal or abnormal levels.

[0118] Therefore, the present invention also provides a method for treating a disease in a subject in need thereof, comprising delivering to the subject an effective amount of the guide editing system of the present invention to modify a gene associated with the disease. The present invention also provides the use of the guide editing system in the preparation of a pharmaceutical composition for treating a disease in a subject in need thereof, wherein the guide editing system is used to modify a gene associated with the disease. The present invention also provides a pharmaceutical composition for treating a disease in a subject in need thereof, comprising the guide editing system of the present invention, and an optional pharmaceutically acceptable carrier, wherein the guide editing system is used to modify a gene associated with the disease.

[0119] Preferably, the "subject" of the present invention is a mammal, such as a human.

[0120] In some embodiments, the prime editing systems described herein are used to introduce point mutations into a nucleic acid.

[0121] In some embodiments, the guide editing system described herein is used to cause the correction of genetic defects, such as in the correction of point mutations that cause loss of function in gene products. In some embodiments, the genetic defect is associated with a disease or condition (e.g., lysosomal storage disease or metabolic disease, such as, for example, type I diabetes). In some embodiments, the methods provided herein can be used to introduce inactivating point mutations into genes or alleles encoding gene products associated with diseases or conditions.

[0122] In some embodiments, the purpose of the scheme described in the present invention is to treat a disease associated with or caused by a point mutation that can be corrected by the guide editing system provided herein. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease.

[0123] In some embodiments, the invention describes a method for treating mitochondrial diseases or disorders. As used herein, "mitochondrial diseases" refer to diseases caused by abnormal mitochondria, such as mitochondrial gene mutations, enzyme pathways, etc. Examples of diseases include, but are not limited to: neurological diseases, loss of motor control, muscle weakness and pain, gastrointestinal diseases and dysphagia, poor growth, heart disease, liver disease, diabetes, respiratory complications, epilepsy, vision / hearing problems, lactic acidosis, developmental delays, and susceptibility to infection.

[0124] Examples of diseases described in the present invention include, but are not limited to, genetic diseases, circulatory system diseases, muscle diseases, brain, central nervous and immune system diseases, Alzheimer's disease, secretase disorders, amyotrophic lateral sclerosis (ALS), autism, trinucleotide repeat expansion disorders, hearing diseases, gene-targeted therapy of non-dividing cells (neurons, muscles), liver and kidney diseases, epithelial cell and lung diseases, cancer, Usher syndrome or retinitis pigmentosa-39, cystic fibrosis, HIV and AIDS, beta thalassemia, sickle cell disease, herpes simplex virus, autism, drug addiction, age-related macular degeneration, schizophrenia. Other diseases treated by correcting point mutations or introducing inactivating mutations into disease-related genes are known to those skilled in the art, and therefore the present disclosure is not limited in this regard. In addition to the diseases exemplarily described in the present invention, other related diseases can also be treated with the strategies and guide editing systems provided by the present invention, and the application is obvious to those skilled in the art. The diseases or targets to which the present invention can be applied refer to WO2015089465A1 (PCT / US2014 / 070135), WO2016205711A1 (PCT / US2016 / 038181), WO2018141835A1 (PCT / EP2018 / 052491), WO2020191234A1 (PCT / US2020 / 023713), WO2020191233A1 (PCT / US2020 / 023712), WO2019079347A1 (PCT / US2018 / 056146), and WO2021155065A1 (PCT / US2021 / 015580) for the related diseases to which the base editing systems are applicable.

[0125] Administration of the guide editing system or pharmaceutical composition of the present invention can be adjusted for the weight and species of the patient or subject. The frequency of administration is within the range permitted by medical or veterinary medicine. It depends on conventional factors including the age, sex, general health, other conditions of the patient or subject, and the specific condition or symptom being addressed.

[0126] 6. Test kit

[0127] The present invention also includes a kit for use in the methods of the present invention, the kit comprising the components of the guide editing system of the present invention. The kit may also include reagents for introducing the guide editing system into an organism or a cell of an organism. The kit generally includes a label indicating the intended use and / or method of use of the contents of the kit. The term label includes any written or recorded material provided on or with the kit or otherwise provided with the kit. Example

[0128] Materials and Methods

[0129] 1. Vector construction

[0130] The vectors were constructed using the existing guide editor vector skeleton in the laboratory. The main vectors constructed are:

[0131] niCPE:

[0132] Cas12a-niCPE

[0133] Cas12a-sniCPE

[0134] Cas12i-niCPE

[0135] nuCPE:

[0136] Cas12a-nuCPE

[0137] Cas12a-snuCPE

[0138] Cas12i-nuCPE

[0139] CirRNA:

[0140] 5'+3'MS2-CirRNA

[0141] guide RNA:

[0142] crRNA(Cas12a)

[0143] crRNA(Cas12i)

[0144] 2. Human HEK293T cell culture and transformation

[0145] 2.1 Thawing cells

[0146] (1) Take the HEK293T cell line out of liquid nitrogen and thaw it in a 37°C water bath for 2 minutes.

[0147] (2) Remove cells from the cryopreservation tube and slowly add them to a 15 mL centrifuge tube containing 10 mL of culture medium.

[0148] (3) Centrifuge at 500 × g for 3 minutes to pellet the cells and remove the supernatant.

[0149] (4) Add 10 mL of culture medium to the precipitate, transfer to a T175 culture flask, and place in a 37°C incubator containing 5% CO2.

[0150] (5) After 24 hours, the culture medium was replaced and the cells were cultured in a 37°C incubator containing 5% CO2.

[0151] 2.2 Cell culture

[0152] (1) Carefully aspirate the cell culture medium from the T175 flask.

[0153] (2) Gently wash the cells with 10 mL of PBS solution.

[0154] (3) Treat the cells with 2 mL of trypsin: Place the T175 cell culture flask in a 37°C incubator for 2 minutes to allow trypsin to fully dissociate the cells.

[0155] (4) Add 10 mL of cell culture medium to the T175 cell culture flask to resuspend the cells and inactivate trypsin.

[0156] (5) Use a 10 mL pipette to pipette up and down the cell suspension to obtain a single cell suspension.

[0157] (6) After diluting the cells at a ratio of 1:10, continue to culture in a 37°C incubator containing 5% CO2.

[0158] 2.3 Cell plating

[0159] (1) Mix 15uL of the single-cell suspension from step 2.1-(5) with 15uL of trypan blue and let stand at room temperature for 1-2 minutes.

[0160] (2) Open a new cell counter. Add 10uL of the mixed cell and trypan blue solution to each of the A and B counting chambers, insert the counting plate into the cell counter and read the count.

[0161] (3) Calculate the required dilution factor so that the final plate count is 45,000 cells per well in 250 uL of cell culture medium in a 48-well plate. Dilution factor = (A count + B count) / (2 × 4 × 45,000).

[0162] (4) Dilute the cells according to the dilution factor and use an adjustable width multichannel pipette to dispense the cell suspension into a 48-well plate, adding 250uL of cell suspension to each well.

[0163] (5) Place the 48-well plate containing cells in a 37°C incubator and culture them for liposome transformation after 16 to 24 hours.

[0164] 2.4 Transfection of cells

[0165] (1) Before transfecting cells, observe the cell growth status under a microscope, preferably at a coverage of 60%.

[0166] (2) Mix 300 ng of protein expression plasmid and 100 ng of RNA expression plasmid in Opti-MEM to a total volume of 12.5 uL.

[0167] (3) Add 1 uL Lipofectamine 2000 and 10-20 ng copGFP expression plasmid to Opti-MEM to make a total volume of 12.5 uL.

[0168] (4) Mix (2) and (3) to a total volume of 25uL solution, incubate for 5-15 minutes, then add to the cell solution in a 48-well plate and culture in a 37°C incubator for 48-72 hours.

[0169] 3. Reporter system fluorescence observation

[0170] After being cultured in a 37°C incubator for 48 hours, human HEK293T cells were observed under a fluorescence microscope or a laser confocal microscope. The efficiency of different guide editors was compared based on fluorescence, and the fluorescence images were saved.

[0171] 4. Human HEK293T cell lysis and amplicon sequencing analysis

[0172] 4.1 Lysis of human HEK293T cells

[0173] (1) After culturing the cells in a 37°C incubator for 72 hours, carefully aspirate the cell culture medium using an adjustable width multichannel pipette.

[0174] (2) Gently add 300uL PBS buffer, shake gently to wash away dead cells, and then aspirate the PBS buffer.

[0175] (3) Add 200uL of lysis buffer (with proteinase K added) and treat at 55°C for 30 minutes.

[0176] (4) Pipette 50uL of cell lysate into a 96-well plate and treat at 95°C for 5 minutes before use.

[0177] 4.2 Amplicon Miseq sequencing analysis

[0178] (1) PCR amplification of human HEK293T cell lysate was performed using Miseq first-round primers.

[0179] The first round of 15 μL amplification system: 7.5 μL 2×Phanta Max Master Mix, 4.5 uL ddH2O, 1 μL Forward primer (10 μM), 1 μL Reverse primer (10 μM), 1 μL cell lysate.

[0180] The conditions for the first round of 15 μL amplification were as follows: pre-denaturation at 95°C for 3 min; denaturation at 95°C for 15 s, annealing at 50-60°C for 15 s, extension at 72°C for 20 s, 34 cycles; full extension at 72°C for 5 min.

[0181] (2) The first round amplification product was diluted 5 times, and 1 μL was used as the template for the second round of PCR amplification. The amplification primers were Miseq second round sequencing primers containing Barcode.

[0182] The second round of 25μL amplification system: 12.5μL 2×Phanta Max Master Mix, 9.5uL ddH2O, 1μL Forward primer (10μM), 1μL Reverse primer (10μM), 1μL DNA template.

[0183] The conditions for the second round of amplification were as follows: pre-denaturation at 95°C for 3 min; denaturation at 95°C for 15 s, annealing at 50-60°C for 15 s, extension at 72°C for 20 s, 10 cycles; full extension at 72°C for 5 min.

[0184] (3) The PCR products were detected by 2% agarose gel electrophoresis, and the target fragments were recovered by gel extraction using AxyPrep DNA Gel Extraction kit. The recovered products were quantitatively analyzed using NanoDrop ultra-micro spectrophotometer; 100 ng of the recovered products were mixed and sent to Beijing Qihe Biotechnology Co., Ltd. for amplicon sequencing analysis.

[0185] (4) After sequencing is completed, the editing type and editing efficiency of the products at different gene targeting sites in the three repeated experiments are compared and analyzed.

[0186] Example 1. The circular RNA-dependent guide editing system Cas12a-CPE repairs copGFP to make human 293T cells produce green fluorescence.

[0187] When the inventors used pegRNA to develop Cas12a-PE guide editors, they found that the efficiency of guide editing was low ( Figure 2 ). According to analysis, it is believed that because Cas12a itself has the activity of cutting RNA, even if the domain of its RNA cutting is mutated, it will still affect pegRNA. Furthermore, because crRNA is very small, only about 20bp, the RTT and PBS sequences of its pegRNA are very easy to complement the Target sequence of crRNA, which greatly hinders the function of pegRNA.

[0188] In 2019, Litke and Jaffrey reported the Tornado (Twister-optimized RNA for durable overexpression) human cell circular RNA expression system ( https: / / doi.org / 10.1038 / s41587-019- 0090-6 ). Tornado uses two ribozymes to cut out the RNA ends, and connects the RNA ends into circular RNA under the action of human cell RNA ligase RtcB. In 2022, Sontheimer (https: / / doi.org / 10.1038 / s41587-022-01255-9) and Ma Hanhui (https: / / doi.org / 10.1093 / procel / pwac014) groups expressed the RTT (reverse transcriptase template) and PBS (primer binding site) sequences of pegRNA (prime editing guide RNA) in the guide editor (primeeditor) into circular RNA to produce sPE (split prime editor) guide editor.

[0189] The inventors surprisingly found that placing the RTT and PBS sequences in pegRNA in circular RNA for stable expression can well avoid the above two problems of the Cas12a guide editing system.

[0190] The guide editor is mainly composed of three parts: nCas protein, reverse transcriptase and pegRNA (prime editing guide RNA). When developing the new guide editor Cas12a-CPE, the viral M-MLV reverse transcriptase has high activity and does not need to be completely changed; while LbCas12a, i.e. LbCpf1, does not have the classic nick single incision form. The inventors found that LbCpf1 with R1138A substitution is the Nickase form of LbCpf1, which has nickase activity, and LbCpf1 with R1138A is used to construct Cas12a-CPE. The third part of the guide editor is pegRNA. The inventors separated the PBS (primerbinding site) and RT (reverse transcriptase) template sequences from pegRNA and placed them in Circular RNA for stable expression. The inventors also designed a copGFP reporter system in which the GFP coding sequence contains a mutation of three bases, and the fluorescence of copGFP can only be restored when the guide editor undergoes precise gene editing.

[0191] Using the above copGFP reporter system, Cas12a-niCPE, Cas12a-nuCPE, Cas12a-sniCPE, Cas12a-snuCPE guide editing system and mutated copGFP plasmid were co-transfected into human HEK293T cells. After about 48 hours of culture, in the presence of Cas12a-niCPE ( Figure 2 i) Cas12a-nuCPE ( Figure 2 h) and Cas12a-sniCPE( Figure 2 o) Obvious copGFP fluorescence was detected in the reporter system, Cas12a-snuCPE ( Figure 2 l) The fluorescence of the guide editing system is weak. Figure 2 a is the positive control with copGFP added, and the negative control without treatment ( Figure 2 b) and the control group with only the mutant copGFP system ( Figure 2 c) No fluorescence, using 3'pegRNA ( Figure 2 de) and 5'pegRNA( Figure 2 The Cas12a-guided editing system constructed by fg also has almost no fluorescence. The guide editing system without reverse transcriptase ( Figure 3 j, m) There is no fluorescence, free reverse transcriptase-guided editing system ( Figure 3 k, n) The fluorescence expression is weak.

[0192] Further use of human HEK293T cell lines to guide editing reporter systems and various target editing efficiency tests revealed that the Cas12a guide editing system constructed using 5'pegRNA and 3'pegRNA had extremely low editing efficiency, while the guide editing system constructed using circular RNA produced precise gene editing ( Figure 3 ).

[0193] Example 2. The circular RNA-dependent guide editing system Cas12a-niCPE achieves precise base editing at the target site in human 293T cells.

[0194] The inventors found that the Cas12a-niCPE-guided editing system based on circular RNA and non-targeted single-chain nickase nCas12a has a strong gene editing efficiency in the reporter system, making the copGFP reporter system emit strong green fluorescence. The inventors further verified the guide editing efficiency of Cas12a-niCPE in the DNMT1-1 target in human 293T cells and found that the base deletion (DEL, deletion), insertion (INS, insertion) and substitution (SUB, substitution) have high guide editing efficiency, among which the highest guide editing efficiency can reach 24.06% ( Figure 4 ).

[0195] Example 3. The circular RNA-dependent guide editing system Cas12a-nuCPE achieves precise base editing at the target site in human 293T cells.

[0196] Although the inventors have found the non-targeted chain single nickase (the chain bound to crRNA is called the targeting chain, and the chain complementary to the targeting chain is called the non-targeting chain) form of Cas12a-R1138A, the newly discovered nuclease may not have the non-targeted chain single nickase form, which greatly limits the development of proteins such as Cas12b (i.e. C2c1), Cas12c, Cas12d (i.e. CasY), Cas12e (i.e. CasX), Cas12f (i.e. Cas14), Cas12h, Cas12i, Cas12j (i.e. CasΦ), Cas12k, Cas12m, IscB and TnpB for guiding the editing system. Therefore, the inventors first developed the Cas12a-nuCPE guided editing system based on circular RNA with wild nuclease Cas12a as a breakthrough. The inventors selected three gene targets in human 293T cells, namely SITE7, SITE8 and SITE10, to further verify the guide editing efficiency of the Cas12a-nuCPE guide editing system in human cells. After testing, it was found that the Cas12a-nuCPE editing system had guide editing efficiency at all three targets ( Figure 5 ).

[0197] Example 4. The detachable circular RNA-dependent guide editing system Cas12a-sniCPE achieves precise base editing at the target site in human 293T cells.

[0198] Base editing systems have gradually shown surprising prospects in the treatment of human diseases. However, since the guide editing system is large, it is not convenient for delivery by viral systems such as AAV. Therefore, the inventors further freed the MCP-MMLV protein and expressed it independently of the nCas12a non-targeted chain single nickase. They developed a detachable guide editing system Cas12a-sniCPE that uses the non-targeted chain single nickase nCas12a and depends on circular RNA. The gene editing efficiency of Cas12a-sniCPE was verified using three gene targets SITE7, SITE8 and SITE10 in human 293T cells, and it was found that the Cas12a-sniCPE editing system had guide editing efficiency ( Figure 6 ).

[0199] Example 5. The detachable circular RNA-dependent guide editing system Cas12a-snuCPE achieves precise base editing at the target site in human 293T cells.

[0200] Also, since the newly discovered nucleases may not have a non-targeted chain single nickase form, this greatly limits the use of proteins such as Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IscB, and TnpB for the development of guide editing systems. Therefore, the inventors further developed a detachable guide editing system Cas12a-snuCPE that utilizes nucleases and relies on circular RNA. The gene editing efficiency of Cas12a-snuCPE was verified using three gene target sites SITE7, SITE8, and SITE10 in human 293T cells, and it was found that the Cas12a-snuCPE editing system had a guide editing efficiency ( Figure 7 ). Further research and comparison found that among the niCPE, nuCPE, sniCPE and snuCPE systems, the niCPE and sniCPE guided editing systems have better editing efficiency ( Figure 8 ), and the off-target sites were verified and it was found that the niCPE and sniCPE guided editing systems had no off-target efficiency in HEK293T ( Fig.11 a).

[0201] Example 6. One-CPE-guided editing system for simultaneous expression of all RNAs.

[0202] Since Cas12a itself has the function of cutting RNA, the same human U6 promoter can be used to drive the simultaneous expression of multiple tandem RNAs, including crRNA, circular RNA containing RTT and PBS, and nicking RNA. Under the action of Cas12a, multiple RNAs are expressed simultaneously. The crRNA is used to bind to the Cas12a protein to find the target site, and the circular RNA expresses RTT and PBS to provide the starting primer and template for the reverse transcriptase. In CPE3, the nicking RNA and Cas12a combine to produce a nick on the distal target chain, further increasing the efficiency of guide editing ( Fig. 9 a). Further verification in HEK293T cell lines revealed that one-CPE has a high guide editing efficiency ( Fig. 9 b). Verification of off-target sites revealed that the one-niCPE and one-sniCPE guided editing systems had no off-target efficiency in HEK293T ( Fig.11b).

[0203] Example 7. Human HEK293T multi-gene Cas12a-CPE guided editing system.

[0204] Cas12a protein has been widely used for multi-gene editing in organisms, but guide editing has not been performed yet. We took advantage of Cas12a's ability to cut RNA and express multiple crRNAs at the same time. More importantly, we simultaneously tandem multiple RTT and PBS sequences in circular RNA ( Fig.10 a). Experiments in the HEK293T human cell line demonstrated that multiple RTTs and PBSs expressed in tandem in circular RNAs resulted in efficient guide editing of different editing sites ( Fig.10 bd). Since many diseases are caused by mutations in multiple targets, we further tested the Cas12a-CPE guide editing system for simultaneous guide editing of two genes, three genes, and even four genes. The results showed that the Cas12a-CPE guide editing system can perform efficient multi-gene guide editing in human HEK293T cells ( Fig.10 e).

[0205] Example 8. The circular RNA-dependent guide editing system Cas12i-niCPE achieves precise base editing at the target site in human 293T cells.

[0206] The four guide editing systems niCPE, nuCPE, sniCPE, and snuCPE developed above all have good guide editing efficiency on Cas12a, and the gene editing efficiency of the particularly Cas12a-niCPE guide editing system is already very high. Therefore, the inventors speculate that most of the newly developed Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IsrB, IscB, and TnpB proteins can be applied to the CPE guide editing system. The inventors then selected the CPE guide editing system developed by Cas12i2 protein for further detection. The inventors first found that two amino acid mutations W954A and T882A may cause Cas12i2 to form a non-targeted chain single nickase form. The inventors used the wild type of Cas12i2 and the non-targeted chain single nickase formed by these two amino acid point mutations to develop Cas12i-nuCPE and Cas12i-niCPE-W854A, Cas12i-niCPE-T882A guide editing systems. Fig.12a) and RNF2( Fig.12 b) Target verification found that Cas12i-niCPE-W854A had a better guide editing efficiency, followed by Cas12i-nuCPE, and Cas12i-niCPE-T882A had a lower guide editing efficiency. This indicates that W854A is a better non-targeted strand nickase form of Cas12i, and Cas12i-niCPE-W854A will be named Cas12i-niCPE in the future.

[0207] sequence:

[0208] SEQ ID NO:1LbCas12a amino acid sequence

[0209] MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLDRYYLSFI

[0210] NDVLHSIKLKNLNNYISLFRKKTRTEKENKELENLEINLRKEIAKAFKGNEGYKSLFKKDII

[0211] ETILPEFLDDKDEIALVNSFNGFTTAFTGFFDNRENMFSEEAKSTSIAFRCINENLTRYISN

[0212] MDIFEKVDAIFDKHEVQEIKEKILNSDYDVEDFFEGEFFNFVLTQEGIDVYNAIIGGFVTES

[0213] GEKIKGLNEYINQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNK

[0214] NSEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFGEWNVIRDKWNAEYDDIHLK

[0215] KKAVVTEKYEDDRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEK

[0216] LFDADFVLEKSLKKNDAVVAIMKDLLDSVKSFENYIKAFFGEGKETNRDESFYGDFVLAYDI

[0217] LLKVDHIYDAIRNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIM

[0218] DKKYAKCLQKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSEDIQKIYKNGT

[0219] FKKGDMFNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYKVSF

[0220] ESASKEVDKLVEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHGQIRLSGGAEL

[0221] FMRRASLKKEELVVHPANSPIANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCP

[0222] KNIFKINTEVRVLLKHDDNPYVIGIDRGERNLLYIVVVDKGGNIVEQYSLNEIINNFNGIRI

[0223] KTDYHSLLDKKEKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSG

[0224] FKNSRVKVEKQVYQKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGF

[0225] IFYIPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISSFDRIMYVPEEDLFEFALDYKNFSR

[0226] TDADYIKKWKLYSYGNRIRIFRNPKKNNVFDWEVCLTSAYKELFNKYGINYQQGDIRALLC

[0227] EQSDKAFYSSFMALMSLMLQMRNSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENAILPKN

[0228] ADANGAYNIARKVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQTSVK

[0229] SEQ ID NO:2 LbCas12a(D156R) Amino Acid Sequence

[0230] MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLDRYYLSFI

[0231] NDVLHSIKLKNLNNYISLFRKKTRTEKENKELENLEINLRKEIAKAFKGNEGYKSLFKKDII

[0232] ETILPEFLDDKDEIALVNSFNGFTTAFTGFFRNRENMFSEEAKSTSIAFRCINENLTRYISN

[0233] MDIFEKVDAIFDKHEVQEIKEKILNSDYDVEDFFEGEFFNFVLTQEGIDVYNAIIGGFVTES

[0234] GEKIKGLNEYINLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNK

[0235] NSEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFGEWNVIRDKWNAEYDDIHLK

[0236] KKAVVTEKYEDDRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEK

[0237] LFDADFVLEKSLKKNDAVVAIMKDLLDSVKSFENYIKAFFGEGKETNRDESFYGDFVLAYDI

[0238] LLKVDHIYDAIRNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIM

[0239] DKKYAKCLQKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSEDIQKIYKNGT

[0240] FKKGDMFNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYKVSF

[0241] ESASKKEVDKLVEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHGQIRLSGGAEL

[0242] FMRRASLKKEELVVHPANSPIANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCP

[0243] KNIFKINTEVRVLLKHDDNPYVIGIDRGERNLLYIVVVDGKGNIVEQYSLNEIINNFNGIRI

[0244] KTDYHSLLDKKEKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSG

[0245] FKNSRVKVEKQVYQKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGF

[0246] IFYIPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISSFDRIMYVPEEDLFEFALDYKNFSR

[0247] TDADYIKKWKLYSYGNRIRIFRNPKKNNVFDWEEVCLTSAYKELFNKYGINYQQGDIRALLC

[0248] EQSDKAFYSSFMALMSLMLQMRNSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENAILPKN

[0249] ADANGAYNIARKVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQTSVK

[0250] SEQ ID NO: 3 LbCas12a (D156R, R1138A) Amino Acid Sequence

[0251] MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLDRYYLSFI

[0252] NDVLHSIKLKNLNNYSLFRKTRTEKENKENLEINLRKEIAKAFKGNEGYKSLFKKDII

[0253] ETILPEFLDDKDEIALVNSFNGFTTAFTGFFRNRENMFSEEAKSTSIAFRCINENLTRYISN

[0254] MDIFEKVDAIFDKHEVQEIKEKILNSDYDVEDFFEGEFNFVLTQEGIDVYNAIIGGFVTES

[0255] GEKIKGLNEYINLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNK

[0256] NSEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFGEWNVIRDKWNAEYDDIHLK

[0257] KKAVVTEKYEDDRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEK

[0258] LFDADFVLEKSLKKNDAVVAIMKDLLDSVKSFENYIKAFGFEGKETNRDESFYGDFVLAYDI

[0259] LLKVDHIYDAIRNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIM

[0260] DKKYAKCLQKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSEDIQKIYKNGT

[0261] FKKGDMFNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYKVSF

[0262] ESASKKEVDKLVEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHGQIRLSGGAEL

[0263] FMRRASLKKEELVVHPANSPIANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCP

[0264] KNIFKINTEVRVLLKHDDNPYVIGIDRGERNLLYIVVVDGKGNIVEQYSLNEIINNFNGIRI

[0265] KTDYHSLLDKKEKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSG

[0266] FKNSRVKVEKQVYQKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGF

[0267] IFYIPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISSFDRIMYVPEEDLFEFALDYKNFSR

[0268] TDADYIKKWKLYSYGNRIRIFRNPKKNNVFDWEEVCLTSAYKELFNKYGINYQQGDIRALLC

[0269] EQSDKAFYSSFMALMSLMLQMANSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENAILPKN

[0270] ADANGAYNIARKVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQTSVK

[0271] SEQ ID NO:4 Cas12i amino acid sequence

[0272] MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVRFSTEQEKQQ

[0273] QDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDAIKQYFSASIGESYYWNDC

[0274] RQQYYDLCRELGVEVSDLTHDLEILCREKCLAVATESNQYNSIISVLFGTGRKEDRSVKLRI

[0275] TKKILEAISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLERFIAKDGQKEF

[0276] DLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRN

[0277] YNFAKQRLEQFKRIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKRLSKLYKAWED

[0278] DPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRYKSQKA

[0279] NPSVLGNQGFTWRNAVILPEKAQRNDRPNSLDLRIWLYLKLRHPDGRWKKHHIPFYDTRFFQ

[0280] EIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSN

[0281] LKITRISATINSKGQVRIPVKFDVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYH

[0282] KELGCFVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKK

[0283] EIVTVEAKEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEIFRFIEQDCGVT

[0284] RLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRK

[0285] KKQKVERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDWLARGVFNKIRQLAP

[0286] MHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIPVKDIGDWVLRKLSQNLRAKNIGTGE

[0287] YYHQGVKEFLSHYELQDLEEELLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRI

[0288] YFATHKVATGAVSIVFDQKQVWVCNADHVAAANIALTVKGIGEQSSDEENPDGSRIKLQLTS

[0289] SEQ ID NO:5 Cas12i(W854A) Amino Acid Sequence

[0290] MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVRFSTEQEKQQ

[0291] QDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDAIKQYFSASIGESYYWNDC

[0292] RQQYYDLCRELGVEVSDLTHDLEILCREKCLAVATESNQYNSIISVLFGTGRKEDRSVKLRI

[0293] TKKILEAISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLERFIAKDGQKEF

[0294] DLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRN

[0295] YNFAKQRLEQFKRIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKRLSKLYKAWED

[0296] DPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRYKSQKA

[0297] NPSVLGNQGFTWRNAVILPEKAQRNDRPNSLDLRIWLYLKLRHPDGRWKKHHIPFYDTRFFQ

[0298] EIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSN

[0299] LKITRISATINSKGQVRIPVKFDVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYH

[0300] KELGCFVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKK

[0301] EIVTVEAKEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEIFRFIEQDCGVT

[0302] RLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRK

[0303] KKQKVERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDALARGVFNKIRQLAP

[0304] MHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIPVKDIGDWVLRKLSQNLRAKNIGTGE

[0305] YYHQGVKEFLSHYELQDLEEELLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRI

[0306] YFATHKVATGAVSIVFDQKQVWVCNADHVAAANIALTVKGIGEQSSDEENPDGSRIKLQLTS

[0307] SEQ ID NO:6 Amino acid sequence of M-MLV reverse transcriptase

[0308] STLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSI

[0309] KQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVE

[0310] DIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTW

[0311] TRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTL

[0312] GNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGF

[0313] CRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVD

[0314] EKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLV

[0315] ILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNC

[0316] LDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTS

[0317] AQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILA

[0318] LLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP

[0319] SEQ ID NO:7 Amino acid sequence of M-MLV reverse transcriptase (ΔRnaseH)

[0320] TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIK

[0321] QYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVED

[0322] IHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWT

[0323] RLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLG

[0324] NLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFC

[0325] RLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDE

[0326] KQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVI

[0327] LAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCL

[0328] DILAEAHGTRPDLTDQPL

[0329] SEQ ID NO:8 MCP amino acid sequence

[0330] ASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQAYKVTCSVRQSSAQNRKYTIKV

[0331] EVPKGAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGNPIPSAIAANSGIY

[0332] SEQ ID NO:9 32aa linker amino acid sequence

[0333] SGGSSGGSSGSETPGTSESATPESSGGSSGGS

[0334] SEQ ID NO:10 NLS amino acid sequence

[0335] MKRTADGSEFESPKKKRKV

[0336] SEQ ID NO:11 NLS amino acid sequence

[0337] KRTADGSEFEPKKKRKV

[0338] SEQ ID NO:12 Cas12a-niCPE: NLS-MCP-32aa Linker-nCas12a(D156R,R1138A)-MMLV

[0339] ΔRnaseH-NLS

[0340] MKRTADGSEFESPKKKRKVKLASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQA

[0341] YKVTCSVRQSSAQNRKYTIKVEVPKGAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGN

[0342] PIPSAIAANSGIYSRLQSGGSSGGSSGSETPGTSESATPESSGGSSGGSELMSKLEKFTNCY

[0343] SLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLDRYYLSFINDVLHSIKLKN

[0344] LNNYISLFRKKTRTEKENKELENLEINLRKEIAKAFKGNEGYKSLFKKDIIETILPEFLDDK

[0345] DEIALVNSFNGFTTAFTGFFRNRENMFSEEAKSTSIAFRCINENLTRYISNMDIFEKVDAIF

[0346] DKHEVQEIKEKILNSDYDVEDFFEGEFNFVLTQEGIDVYNAIIGGFVTESGEKIKGLNEYI

[0347] NLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNKNSEIFSSICKL

[0348] EKLFKNFDEYSSAGIFVKNGPAISTIKDIFGEWNVIRDKWNAEYDDIHLKKKAVVTEKYED

[0349] DRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEKLFDADFVLEKS

[0350] LKKNDAVVAIMKDLLDSVKSFENYIKAFGFEGKETNRDESFYGDFVLAYDILLKVDHIYDAI

[0351] RNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIMDKKYAKCLQKI

[0352] DKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYNPSEDIQKIYKNGTFKKGDMFNLND

[0353] CHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYKVSFESASKEVDKL

[0354] VEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHGQIRLSGGAELFMRRASLKEE

[0355] LVVHPANSPIANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCPKNIFKINTEVR

[0356] VLLKHDDNPYVIGIDRGERNLLYIVVVDKGGNIVEQYSNLNEIINNFNGIRIKTDYHSLLDKK

[0357] EKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSGFKNSRVKVEKQ

[0358] VYQKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGFIFYIPAWLTSK

[0359] IDPSTGFVNLLKTKYTSYADSKKFISSFDRIMYVPEEDLFEFALDYKNFSRTDADYIKKWKL

[0360] YSYGNRIRIFRNPKKNNVFDWEEVCLTSAYKELFNKYGINYQQGDIRALLCEQSDKAFYSSF

[0361] MALMSLMLQMANSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENAILPKNADANGAYNIAR

[0362] KVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQTSVKSGGSSSGGSSGSETPGTSESATPES

[0363] SGGSSGGSPGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP

[0364] LKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQ

[0365] DLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDP

[0366] EMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQ

[0367] QGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ

[0368] LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPD

[0369] LTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDA

[0370] GKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLSGGSKRTADGSEFEPKKKRKV*

[0371] SEQ ID NO:13 Cas12a-nuCPE:NLS-MCP-32aaLinker-Cas12a(D156R)-MMLVΔRnaseH-

[0372] NLS

[0373] MKRTADGSEFESPKKKRKVKLASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQA

[0374] YKVTCSVRQSSAQNRKYTIKVEVPKGAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGN

[0375] PIPSAIAANSGIYSRLQSGGSSGGSSGSETPGTSESATPESSGGSSGGSELMSKLEKFTNCY

[0376] SLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLDRYLFSFINDVLHSIKLKN

[0377] LNNYSLFRKKTRTEKENKENLEINLRKEIAKAFKGNEGYKSLFKKDIIETILPEFLDDK

[0378] DEIALVNSFNGFTTAFTGFFRNRENMFSEEAKSTSIAFRCINENLTRYISNMDIFEKVDAIF

[0379] DKHEVQEIKEKILNSDYDVEDFFEGEFNFVLTQEGIDVYNAIIGGFVTESGEKIKGLNEYI

[0380] NLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRNTLNKNSEIFSSICKL

[0381] EKLFKNFDEYSSAGIFVKNGPAISTIKDIFGEWNVIRDKWNAEYDDIHLKKKAVVTEKYED

[0382] DRRKSFKKIGSFSLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEKLFDADFVLEKS

[0383] LKKNDAVVAIMKDLLDSVKSFENYIKAFGFEGKETNRDESFYGDFVLAYDILLKVDHIYDAI

[0384] RNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIMDKKYAKCLQKI

[0385] DKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYNPSEDIQKIYKNGTFKKGDMFNLND

[0386] CHKLIDFFKDSISRYPKWSNAYDFNFSETEKYKDIAGFYREVEEQGYKVSFESASKEVDKL

[0387] VEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHGQIRLSGGAELFMRRASLKEE

[0388] LVVHPANSPIANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCPKNIFKINTEVR

[0389] VLLKHDDNPYVIGIDRGERNLLYIVVVDKGGNIVEQYSNLNEIINNFNGIRIKTDYHSLLDKK

[0390] EKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSGFKNSRVKVEKQ

[0391] VYQKFEKMLIDKLNYMVDKKSNPCATGGALKGYQITNKFESFKSMSTQNGFIFYIPAWLTSK

[0392] IDPSTGFVNLLKTKYTSYADSKKFISSFDRIMYVPEEDLFEFALDYKNFSRTDADYIKKWKL

[0393] YSYGNRIRIFRNPKKNNVFDWEEVCLTSAYKELFNKYGINYQQGDIRALLCEQSDKAFYSSF

[0394] MALMSLMLQMRNSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENAILPKNADANGAYNIAR

[0395] KVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQTSVKSGGSSSGGSSGSETPGTSESATPES

[0396] SGGSSGGSPGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP

[0397] LKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQ

[0398] DLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDP

[0399] EMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQ

[0400] QGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQ

[0401] LREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPD

[0402] LTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDA

[0403] GKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLSGGSKRTADGSEFEPKKKRKV*

[0404] SEQ ID NO:14 Cas12i-niCPE:NLS-MCP-32aa Linker-Cas12i2max(W854A)-MMLVΔRnaseH-NLS

[0405] MKRTADGSEFESPKKKRKVKLASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQA

[0406] YKVTCSVRQSSAQNRKYTIKVEVPKGAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGN

[0407] PIPSAIAANSGIYSRLQSGGSSGGSSGSETPGTSESATPESSGGSSGGSELMSSAIKSYKSV

[0408] LRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVRFSTEQEKQQQDIALWCAVNW

[0409] FRPVSQDSLTTHTIASDNLVEKFEEYYGGTASDAIKQYFSASIGESYYWNDCRQQYYDLCREL

[0410] GVEVSDLTHDLEILCREKCLAVATESNQYNSIISVLFGTGRKEDRSVKLRITKKILEAISNL

[0411] KEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLERFIAKDGQKEFDLKKLQTDLKK

[0412] VIRGKSKERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRLEQF

[0413] KRIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKRLSKLYKAWEDDPADPENAIVV

[0414] LCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRYKSQKANPSVLGNQGFT

[0415] WRNAVILPEKAQRNDRPNSLDLRIWLYLKLRHPDGRWKKHHIPFYDTRFFQEIYAAGNSPVD

[0416] TCQFRTPRFGYHLPKLTDQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSNLKITRISATIN

[0417] SKGQVRIPVKFDVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELGCFVRFIS

[0418] SGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEAKEKF

[0419] DAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEIFRFIEQDCGVTRLGSLSLSTLE

[0420] TVKAVKGI IYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRKKKQKVERIANS

[0421] LIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDALARGVFNKIRQLAPMHNITLFGCGS

[0422] LISTENSHQDPLVHRNPDKAMKCRWAAIPVKDIGDWVLRKLSQNLRAKNIGTGEYYHQGVKEFLS

[0423] HYELQDLEEELLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGA

[0424] VSIVFDQKQVWVCNADHVAAANIALTVKGIGEQSSDEENPDGSRIKLQLTSSGGSSGGSSGS

[0425] ETPGTSESATPESSGGSSGGSPGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGG

[0426] MGLAVRQAPLI IPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLP

[0427] VKKPGTDISHRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHP

[0428] TSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVD

[0429] DLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKE

[0430] TVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIK

[0431] QALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCL

[0432] RMVAAIAVLTKDAYKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQF

[0433] GPVVALNPATLLPLPEEGLQHNCLDILAAHGTRPDLTDQPLSGGSKRTADGSEFEPKKKRKV*

[0434] SEQ ID NO:15 Cas12i-nuCPE:NLS-MCP-32aa Linker-Cas12i2max-MMLVΔRnaseH-NLSMKRTADGSEFESPKKKRKVKLASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQAYKVTCSVRQSSAQNRKYTIKVEVPKGAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGNPIPSAIAANSGIYSRLQSGGSSGGSSGSETPGTSESATPESSGGSSGGSELMSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVRFSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDAIKQYFSASIGESYWNDCRQQYYDLCRELGVEVSDLTHDLEILCREKCLAVATESNQYNSI ISVLFGTGRKEDRSVKLRITKKILEAISNLKEIPKNVAPIQEIILNVAKATKETFRQVYAGNLGAPSTLERFIAKDGQKEFDLKKLQTDLKKVIRGKSKERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRLEQFKRIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKRLSKLYKAWEDDPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRYKSQKANPSVLGNQGFTWRNAVILPEKAQRNDRPNSLDLRIWLYLKLRHPDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIRVNKKHVKAAKTEARIRLAIQQGTLPVSNLKITRISATINSKGQVRIPVKFDVGRQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELGCFVRFISSGDIVSITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEAKEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEIFRFIEQDCGVTRLGSLSLSTLETVKAVKGI IYSYFSTALNASKNNPISDEQRKEFDPELFALLEKLELIRTRKKKQKVERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKANSRSMDWLARGVFNKIRQLAPMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRWAAIPVKDIGDWVLRKLSQNLRAKNIGTGEYYHQGVKEFLSHYELQDLEEELLKWRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGAVSIVFDQKQVWVCNADHVAAANIALTVKGIGEQSSDEENPDGSRIKLQLTSSGGSSGGSSGSETPGTSESATPESSGGSSGGSPGSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLSGGSKRTADGSEFEPKKKRKV*

[0435] SEQ ID NO:16MCP-MMLV:NLS-MCP-MMLV-NLS

[0436] MKRTADGSEFESPKKKRKVKLASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQA

[0437] YKVTCSVRQSSAQNRKYTIKVEVPKGAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGN

[0438] PIPSAIAANSGIYSRSGGSSGGSSGSETPGTSESATPESSGGSSGGSSTLNIEDEYRLHETS

[0439] KEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKP

[0440] HIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSG

[0441] LPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFN

[0442] EALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQIC

[0443] QKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPL

[0444] YPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLG

[0445] PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPP

[0446] DRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLT

[0447] DQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKM

[0448] AEGKKLNVYTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIIH

[0449] CPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFEPKKKRKV*

[0450] SEQ ID NO:17 MS2 sequence

[0451] GCACATGAGGATCACCCATGTGC

[0452] SEQ ID NO:18 hU6-5’+3’ MS2-CircularRNA: hU6-Ribozyme1-Arm1-5’ MS2-BsaI×2-3’ MS2-Arm2-Ribozyme2- polyT

[0453] GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGAT

[0454] AATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGT

[0455] AATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTT

[0456] ACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACAC

[0457] CGGCCATCAGTCGCCGGTCCCAAGCCCGGATAAAATGGGAGGGGGCGGGAAACCGCCTAACC

[0458] ATGCCGACTGATGGCAGAACTAAGCACATGAGGATCACCCATGTGCCGAGACCTTCCGATAG

[0459] GTCTCCAAGGCACATGAGGATCACCCATGTGCTAAATTAACACTGCCATCAGTCGGCGTGGA

[0460] CTGTAGAACACTGCCAATGCCGGTCCCAAGCCCGGATAAAAGTGGAGGGTACAGTCCACGC T

[0461] TTTTTTT

[0462] SEQ ID NO:19 5’ Ribozyme coding sequence

[0463] GCCATCAGTCGCCGGTCCCAAGCCCGGATAAAATGGGAGGGGGCGGGAAACCGCCT

[0464] SEQ ID NO:20 3’ Ribozyme coding sequence

[0465] AACACTGCCAATGCCGGTCCCAAGCCCGGATAAAAGTGGAGGGTACAGTCCACGC

[0466] SEQ ID NO:21 5' loop arm

[0467] AACCATGCCGACTGATGGCAG

[0468] SEQ ID NO:22 3' loop arm

[0469] CTGCCATCAGTCGGCGTGGACTGTAG

[0470] SEQ ID NO:23Cas12a-crRNA scaffold coding sequence

[0471] TAATTTCTACTAAGTGTAGAT

[0472] SEQ ID NO:24Cas12i-crRNA scaffold coding sequence

[0473] AGAAATCCGTCTTTCATTGACGG

Claims

1. A guide editing system for targeted modification of an organism's genomic DNA sequence, comprising: i) a) a CRISPR nuclease and / or an expression construct comprising a nucleotide sequence encoding said CRISPR nuclease, and a reverse transcriptase and / or an expression construct comprising a nucleotide sequence encoding said reverse transcriptase, or b) a guide editing fusion protein and / or an expression construct containing a nucleotide sequence encoding the guide editing fusion protein, wherein the guide editing fusion protein comprises a CRISPR nuclease and a reverse transcriptase; ii) an editing guide RNA (gRNA) directed against a target sequence in genomic DNA and / or an expression construct containing a nucleotide sequence encoding the editing gRNA; and iii) a circular RNA containing a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence and / or an expression construct containing a nucleotide sequence encoding the circular RNA, Preferably, the CRISPR nuclease is not a Cas9 nuclease or a variant thereof.

2. The guide editing system of claim 1, wherein the CRISPR nuclease is selected from Cas12a (i.e., Cpf1), Cas12b (i.e., C2c1), Cas12c, Cas12d (i.e., CasY), Cas12e (i.e., CasX), Cas12f (i.e., Cas14), Cas12h, Cas12i, Cas12j (i.e., CasΦ), Cas12k, Cas12m, IsrB, IscB, and TnpB.

3. The guide editing system of claim 1 or 2, wherein the CRISPR nuclease is a nickase form thereof.

4. The guide editing system of claim 1 or 2, wherein the CRISPR nuclease is Cas12a, which comprises the amino acid sequence shown in SEQ ID NO: 1 or 2.

5. The guide editing system of claim 1 or 2, wherein the CRISPR nuclease is a Cas12a nickase, which is substituted at the amino acid position 1138 relative to SEQ ID NO: 1 or 2, for example, the amino acid R at position 1138 is substituted by A, preferably, the CRISPR nuclease comprises the amino acid sequence shown in SEQ ID NO:

3.

6. The guide editing system of claim 1 or 2, wherein the CRISPR nuclease is Cas12i, which comprises the amino acid sequence shown in SEQ ID NO:

4.

7. The guide editing system of claim 1 or 2, wherein the CRISPR nuclease is a Cas12i nickase, which is substituted at the amino acid position 854 relative to SEQ ID NO: 4, for example, the amino acid W at position 854 is substituted by A, preferably, the Cas12i nickase comprises the amino acid sequence shown in SEQ ID NO:

5.

8. The guide editing system of any one of claims 1 to 7, wherein the reverse transcriptase is M-MLV reverse transcriptase, such as an M-MLV reverse transcriptase comprising the amino acid sequence shown in SEQ ID NO:

6.

9. The guide editing system of claim 8, wherein the RNase H domain of the M-MLV reverse transcriptase is mutated or deleted.

10. The guide editing system of claim 9, wherein the M-MLV reverse transcriptase with a mutated or deleted RNase H domain comprises the amino acid sequence shown in SEQ ID NO:

7.

11. The guide editing system of any one of claims 1 to 10, wherein the reverse transcriptase and / or the guide editing fusion protein may further comprise one or more RNA aptamer binding protein sequences.

12. The guide editing system of claim 11, wherein the RNA aptamer binding protein is an MCP protein, for example, the MCP comprises the amino acid sequence shown in SEQ ID NO:

8.

13. The guide editing system of claim 1, wherein the guide editing fusion protein of i)-b) comprises an amino acid sequence selected from one of SEQ ID NOs: 12-15, preferably comprises the amino acid sequence of SEQ ID NO:

12.

14. The guide editing system of claim 1, wherein the CRISPR nuclease in i)-a) comprises an amino acid sequence selected from one of SEQ ID NOs: 1-5, preferably an amino acid sequence of SEQ ID NOs: 3 or 5; and the reverse transcriptase comprises the amino acid sequence shown in SEQ ID NO:

16.

15. The guide editing system of any one of claims 1-14, wherein the guide RNA (gRNA) comprises a scaffold sequence shown in SEQ ID NO: 23 or 24.

16. The guide editing system of any one of claims 1 to 15, wherein in the circular RNA, a reverse transcription template (RTT) sequence and a primer binding site (PBS) sequence are directly linked, and the RTT sequence is located at the 5' end of the PBS sequence.

17. The guide editing system of any one of claims 1 to 16, wherein the circular RNA further comprises one or more RNA aptamer sequences, such as the MS2 sequence shown in SEQ ID NO:

17.

18. The guide editing system of any one of claims 1 to 17, wherein the primer binding site sequence is set to be complementary to at least a portion of the target sequence, preferably, the primer binding site sequence is complementary to at least a portion of the 3' free single strand caused by the nick in the DNA chain where the target sequence is located, in particular, is complementary to the nucleotide sequence at the 3' end of the 3' free single strand.

19. The guide editing system of any one of claims 1 to 18, wherein the RTT sequence is set to correspond to a sequence downstream of the target sequence nick, but contains a desired modification, wherein the desired modification comprises a substitution, deletion and / or addition of one or more nucleotides.

20. The guide editing system of any one of claims 1-19, further comprising a nicking gRNA and / or an expression construct containing a nucleotide sequence encoding the nicking gRNA, wherein the nicking gRNA comprises a leader sequence and a scaffold sequence, wherein the leader sequence is configured to have sufficient sequence identity with a nicking target sequence in the genome so as to be able to target the CRISPR nuclease or the fusion protein to the nicking target sequence and cause a nick within the nicking target sequence, wherein the nicking target sequence and the target sequence of the editing gRNA are located on opposite strands of the genomic DNA, and the nick induced by the nicking gRNA and the nick induced by the editing gRNA are about 1 to about 300 nucleotides apart.

21. The guide editing system of any one of claims 1 to 20, wherein the guide editing system comprises a plurality of editing gRNAs and / or an expression construct containing a nucleotide sequence encoding the plurality of editing gRNAs, and accordingly, the circular RNA comprises a plurality of sets of RTT-PBS sequences corresponding to the plurality of editing gRNAs in series.

22. The guide editing system of claim 21, wherein the multiple editing gRNAs target different target sequences, and the corresponding multiple sets of RTT-PBS sequences are used to introduce different modifications into the different target sequences.

23. The guide editing system of any one of claims 1 to 22, wherein the expression construct containing the nucleotide sequence encoding the circular RNA further contains elements required for achieving RNA circularization.

24. The guide editing system of any one of claims 1 to 23, wherein the "expression construct containing a nucleotide sequence encoding the circular RNA" comprises the following coding sequence: 5'-first ribozyme-first looping arm-RTT-PBS-second looping arm-second ribozyme-3', and when transcribed into RNA in the cell, the first ribozyme and the second ribozyme can self-cleave to produce "5'-first looping arm-RTT-PBS-second looping arm-3'", and the first looping arm and the second looping arm can be connected to each other to form a circular RNA containing RTT and PBS.

25. The guide editing system of claim 24, wherein the first ribozyme comprises the nucleotide sequence shown in SEQ ID NO: 19, the second ribozyme comprises the nucleotide sequence shown in SEQ ID NO: 20, the first loop-forming arm comprises the nucleotide sequence shown in SEQ ID NO: 21, and the second loop-forming arm comprises the nucleotide sequence shown in SEQ ID NO:

22.

26. The guide editing system of any one of claims 1-25, wherein the editing gRNA and the circular RNA and optionally the nicking gRNA are encoded by the same expression construct.

27. The guide editing system of claim 26, wherein the expression construct comprises (eg, from 5' to 3' direction) a nucleotide sequence encoding the circular RNA, a nucleotide sequence encoding the editing gRNA, and optionally a nucleotide sequence encoding the nicking gRNA.

28. The guide editing system of claim 27, wherein the nucleotide sequence encoding the circular RNA, the nucleotide sequence encoding the editing gRNA, and optionally the nucleotide sequence encoding the nicking gRNA are driven to express by the same promoter, such as the U6 promoter.

29. A method for producing genetically modified cells, comprising introducing the guide editing system of any one of claims 1-28 into at least one of the cells, thereby resulting in modification of the genomic sequence of the at least one cell.

30. The method of claim 29, wherein the cell is from a mammal such as a human, mouse, rat, monkey, dog, pig, sheep, cow, cat; poultry such as chicken, duck, goose; a plant, including monocots and dicots, for example, rice, corn, wheat, sorghum, barley, soybean, peanut, Arabidopsis.

Citation Information

Cited By

  • Pilot editing system based on PERV reverse transcriptase

    CN118995664A

  • Pilot editing system based on perv reverse transcriptase

    CN118995664B

  • Reverse prime editing system

    WO2026045988A1